Examine the validity and reliability of UTRS in the assessment of essential tremor (ET) and Parkinson tremor.

Do you have a pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma of the oral cavity? If so, you may be able to participate in a phase II/III research study to determine how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer.

The purpose of this research study is to explore benefits of workplace social connection following coffee meetups with colleagues. Must be a full-time UNC employee to participate.

In this study, we want to find out if a new treatment is helpful to couples in which both partners use substances and want to reduce their substance use together. This treatment combines couples therapy and substance use treatment to help couples work as a team around their substance use and build long-lasting ways to meaningfully experience life together.

To evaluate the safety and efficacy of BLU-222 therapy in patients with advanced solid tumors.

Do you have stage 1, HER2-positive breast cancer? Has your surgery already been completed? If so, you may be able to take part in a study to help us learn more about a combination of medications to treat your cancer.

Do you plan to undergo radiation therapy for a cancer in the abdomen or pelvic region? You may be able to take part in a research study to help us learn if a fatty acid supplement can improve quality of life by limiting GI upset during radiation therapy.

Do you have metastatic or recurrent lung cancer? Have you already been treated with chemotherapy or immunotherapy? If so, you may qualify for the LungMap protocol, which will help us identify clinical trials you may be eligible for.

Have you been recently diagnosed with Acute Lymphoblastic Leukemia? If so, you may be able to take part in a research study to help us learn more about the effects of using Tyrosine Kinase Inhibitor (TKI), steroids and blinatumomab versus treatment with steroids, Tyrosine Kinase Inhibitor (TKI) and chemotherapy.

This is a study to learn more about the safety and effectiveness of PT217 to treat advanced cancers. We are looking for patients with small cell lung cancer, large cell neuroendocrine cancer, neuroendocrine prostate cancer or gastroenteropancreatic neuroendocrine carcinomas to take part.